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Summary
Adequate pre-dialysis care reduces mortality among end-stage renal disease (ESRD) patients. We 
tested the hypothesis that individuals with ESRD due to sickle cell disease (SCD–ESRD) 
receiving pre-ESRD care have lower mortality compared to individuals without pre-ESRD care. 
We examined the association between mortality and pre-ESRD care in incident SCD–ESRD 
patients who started haemodialysis between 1 June, 2005 and 31 May, 2009 using data provided 
by the Centers for Medicare and Medicaid Services (CMS). SCD–ESRD was reported for 410 
(0·1%) of 442 017 patients. One year after starting dialysis, 108 (26·3%) patients with incident 
ESRD attributed to SCD died; the hazard ratio (HR) for mortality among patients with SCD–
ESRD compared to those without SCD as the primary cause of renal failure was 2·80 (95% 
confidence interval [CI] 2·31–3·38). Patients with SCD–ESRD receiving pre-dialysis nephrology 
care had a lower death rate than those with SCD–ESRD who did not receive pre-dialysis 
nephrology care (HR = 0·67, 95% CI 0·45–0·99). The one-year mortality rate following an ESRD 
diagnosis was almost three times higher in individuals with SCD when compared to those without 
SCD but with ESRD and could be attenuated by pre-dialysis nephrology care.
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Sickle cell disease (SCD) is a genetic disorder that occurs among approximately 1 in 365 
Blacks or African Americans in the United States (Hassell, 2010). Prior to recent 
innovations in treatment protocols that have increased the life expectancy for this 
population, children born with SCD often died during early adolescence (Platt et al, 1994). 
Now, almost 94% of children with SCD are expected to become adults (Quinn et al, 2010). 
Chronic kidney disease (CKD) occurs among approximately 30% of these individuals and a 
proportion of them will develop end-stage renal disease (ESRD) (Powars et al, 1991). Renal 
replacement therapy (RRT) with dialysis (haemo or peritoneal) or kidney transplantation 
substantially extends the life expectancy of individuals with ESRD.
The first-year United States mortality rate among all patients using haemodialysis is quite 
high. However, appropriate medical care prior to the start of RRT decreases the risk of early 
death (Bradbury et al, 2007; McClellan et al, 2009). Appropriate medical care, defined by 
widely disseminated clinical practice guidelines, includes nephrology referral at least 6 
months before the anticipated start of RRT and the placement of a functioning arteriovenous 
fistula (AVF) prior to the initiation of haemodialysis (National Kidney Foundation, 2001a, 
2002). Despite the importance of early pre-ESRD care for patient well-being and survival, 
recent studies have reported that fewer than half of all patients with incident ESRD have 
seen a nephrologist and fewer than one in five have an AVF in place at the start of dialysis 
(Collins et al, 2009). For special populations, such as individuals with SCD, adequate 
precare prior to RRT might be particularly beneficial to lower their risk for adverse 
outcomes and improve survival.
The relationship between mortality and pre-ESRD care among individuals with SCD has not 
been examined previously. We tested the hypothesis that pre-ESRD care is associated with 
lower mortality among individuals with SCD.
Methods
Study design and population
We conducted a population-based cohort study of patients with incident ESRD with a 
diagnosis of SCD listed as their primary cause of renal failure. Dialysis facilities are 
required by federal law to provide the Centers for Medicare and Medicaid Services (CMS) 
with information on all patients receiving RRT. Patients starting RRT with haemodialysis as 
their initial treatment modality during the period from 1 June, 2005 to 31 May, 2009, were 
included in our cohort. Patients were included in the analysis if they were younger than 100 
years of age. Mortality was ascertained from the start date of the initial haemodialysis 
treatment until death or the last day of follow up. This study was approved by the Emory 
University institutional review board.
Data sources
Participant information was obtained from the Form CMS-2728, which is completed for all 
patients at the start of incentre or home haemodialysis and confirmed as accurate by a 
physician. Data elements for this study included: age category (<65 years vs. ≥65 years), 
sex, race as recorded on the Form CMS-2728 (‘Black or African American’ versus ‘White’), 
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height and weight used to calculate body mass index (BMI), the primary cause of ESRD, 
past medical history, the patient’s type of vascular access at the initiation of haemodialysis, 
and laboratory values for haemoglobin concentrations, serum, creatinine, and serum albumin 
before and after the start of dialysis. The race category was restricted to patients identified as 
‘Black or African American’ or ‘White’ on the Form CMS-2728 because of the small 
numbers of patients in other racial groups. Form CMS-2728 contains information on pre-
existing comorbid conditions that are not listed as the primary cause of ESRD, which 
include diabetes mellitus (DM), congestive heart failure (CHF), atherosclerotic 
cardiovascular disease (ASHD), cerebrovascular disease (CVA or TIA), peripheral vascular 
disease (PVD), and history of hypertension (HxHT). If a comorbid condition was not 
indicated on the Form CMS-2728, we assumed for the purposes of this analysis that it was 
not present. Functional status (amputation, inability to ambulate, needs assistance 
ambulating, and institutionalized at the start of haemodialysis), employment status 6 months 
prior to starting haemodialysis, and insurance status as assessed by dialysis facility staff 
were abstracted from the Form CMS-2728.
Study variables
Sickle cell disease—The attending nephrologist attested to the accuracy of the recorded 
primary diagnosis before Form CMS-2728 was submitted to CMS. We defined a patient as 
having a diagnosis of SCD-ESRD if ‘sickle cell disease/anaemia’ was designated on the 
Form CMS-2728 as the primary cause of renal failure.
Outcome—The outcome of our study was all-cause mortality following the start of 
haemodialysis. Follow-up for each patient began on the day of the first dialysis treatment 
and patients who did not die were censored (their follow-up ended) at the completion of the 
study period. Mortality was identified by monitoring death notification forms routinely 
submitted to CMS-funded ESRD Networks by dialysis facility staff.
Pre-ESRD care—Characteristics of pre-ESRD care recorded on the Form CMS-2728 
included the presence and duration of nephrology care prior to starting dialysis and whether 
a functional AVF for vascular access was in place at the start of dialysis or a central venous 
catheter was used instead. Pre-ESRD nephrology care was ascertained on the Form 
CMS-2728 with the following question: ‘Prior to ESRD therapy: Was patient under care of a 
nephrologist?’ If the answer was ‘yes,’ the duration of care was indicated as either ‘6–12 
months’ or >12 months. We defined two levels of nephrology care: (i) any pre-ESRD 
nephrology care as defined by ‘yes’ to the root of this question and (ii) pre-ESRD care with 
a duration of 6 or more months defined as the sum of those answering either answering ‘6–
12 months’ or ‘>12 months’.
Arteriovenous fistula and catheter use at the start of haemodialysis was ascertained on pre-
dialysis by asking, ‘What access was used on first outpatient dialysis?’ Possible responses 
were: (i) ‘AVF,’ (ii) ‘Graft,’ (iii) ‘Catheter,’ and (iv) ‘Other.’ We defined a functioning AVF 
or catheter to be present if the method of vascular access used on the first outpatient dialysis 
treatment was reported on the Form CMS-2728 to be an AVF or catheter, respectively.
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Means and proportions were used to describe individual characteristics and chi-square tests 
and analysis of variance to test the associations among study variables. Using logistic 
regression, we examined the independent associations between SCD–ESRD and pre-ESRD 
care. We conducted general linear models to control for clustering within ESRD Network 
areas and assessed patient characteristics that were individually associated with a higher risk 
of death. In these analyses, we controlled for age, sex, race (‘Black or African American 
versus ‘White’), BMI, a set of comorbid conditions (DM, CHF, ASHD, PVD, and HxHT), 
and a set of functional status variables (amputation, inability to ambulate, and residence in 
an institutional setting), as well as unemployment and no health insurance prior to starting 
dialysis.
Kaplan–Meier (KM) survival curves were obtained using the log rank test to assess if 
survival for patients with or those without SCD as the primary cause of renal failure was 
statistically different. We then conducted Cox regression models to determine patient 
characteristics that were associated individually with higher risk of death, adjusting for 
potential confounding factors that included age category, sex, race, cause of ESRD, 
comorbid conditions, functional status, unemployment, health insurance status at the start of 
RRT, haemoglobin level, and ESRD Network. Our modelling strategy, to obtain the best 
model, was based on a priori consideration of bivariate analyses and clinical judgment to 
select the most important variables. The three most prevalent comorbidities were used for 
the final model. Given the small sample of SCD–ESRD patients and the large number of 
covariates, we also performed a model using back-ward elimination to achieve the most 
parsimonious model. We calculated adjusted hazard ratios (HRs) with their associated 95% 
confidence intervals (CIs) and checked the proportional hazard assumption using the 
graphical method. The precare analysis was performed without controlling for ESRD 
Network due to the insufficient numbers of patients across Networks. Finally, these analyses 
were repeated with only ‘Black or African American’ patients and the results were not 
changed substantively. These analyses were performed using SAS version 9.1 (SAS Institute 
Inc., Cary, NC, USA).
Results
There were 442 099 patients with incidental ESRD that received haemodialysis within the 
study time frame between 1 June, 2005 and 31 May, 2009. We excluded 80 patients with 
incomplete data, none of whom had SCD, resulting in a sample of 442 019 eligible ESRD 
incident haemodialysis patients. Of these, 410 individuals had a diagnosis of SCD–ESRD, 
representing 0·1% of all patients with incident ESRD that received haemodialysis. Fifty-
three per cent of patients with SCD–ESRD were male. The mean age of those with SCD–
ESRD was 42·8 [standard deviation (SD) = 12·6] years and 97·6% were identified as ‘Black 
or African American.’
Patients with SCD–ESRD were less likely to be 65 years of age or older compared with 
other haemodialysis patients with incident ESRD [odds ratio (OR) = 0·06, 95% CI 0·03–
0·11] (Table I). Further, individuals with SCD–ESRD were less likely than other incident 
ESRD haemodialysis patients to have a history of treated DM (OR = 0·08 95% CI 0·05–
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0·12), ASHD (OR = 0·42, 95% CI 0·21–0·85), and HxHT (OR = 0·50, 95% CI 0·41–0·60) 
(Table I), but they were more likely than other patients with incident ESRD to have a history 
of CHF (OR = 1·72, 95% CI 1·39–2·13) and stroke (OR = 1·39, 95% CI 1·16–1·65). In 
contrast to their counterparts, patients with SCD–ESRD had significantly lower BMI (OR = 
0·21, 95% CI 0·18–0·26). Further, patients with SCD–ESRD were more likely than the other 
ESRD patients to be unemployed (OR = 1·40, 95% CI 1·05–1·87), but less likely to be 
uninsured (OR = 0·23, 95% CI 0·17–0·31). Between those with and those without SCD–
ESRD, there were significant differences in the level of anaemia at the time of the initiation 
of haemodialysis (mean haemoglobin, 79 vs. 100 g/l, P ≤ 0·0001) and mean serum 
creatinine (6·6 vs. 6·0 μmol/l, P ≤ 0·0001). The prevalence of severe anaemia (haemoglobin 
70–90 g/l) was higher among individuals with SCD–ESRD, 70·9% of all subjects compared 
to 24·9% of the other ESRD patients.
The majority of patients with SCD–ESRD (53·9%) reported seeing a nephrologist prior to 
starting haemodialysis, with fewer than half (43·9%) reporting being under the care of a 
nephrologist for 6 months or longer prior to starting haemodialysis (Table II). After 
controlling for all confounding factors, patients with SCD–ESRD were more likely than the 
other ESRD patients to have seen a nephrologist both prior to starting haemodialysis (OR = 
1·24, 95% CI 1·04–1·48) and for 6 months or longer prior to the start of treatment (OR = 
1·25, 95% CI 1·10–1·43) (Table II).
At the start of dialysis, a functioning AVF was reported present among 6·8% of patients with 
SCD–ESRD, 11·9% of ‘Black or African American’ patients without SCD–ESRD and 
13·5% of ‘White’ patients without SCD–ESRD. Patients with SCD–ESRD were less likely 
to have started haemodialysis with an AVF than other ESRD patients (OR = 0·61, 95% CI 
0·40–0·92). The majority of individuals with SCD–ESRD (76·1%) started dialysis with a 
central venous catheter, and were as likely to have a catheter for the first haemodialysis (OR 
= 0·95, 95% CI 0·74–1·22) as other incident patients (Table II).
During the 4·25 years of follow-up, there were 183 deaths among individuals with SCD–
ESRD, accounting for 44·6% of all patients with SCD–ESRD. In contrast, there were 152 
496 (34·5%) deaths among other incident ESRD patients. The median follow-up time for all 
patients with ESRD was 529·0 d (range: 0–1553 d; SD = 606·1). Further, among patients 
with ESRD attributed to SCD, the median follow-up was 467·5 d (range: 17–1545 d; SD = 
574·0). The fully adjusted HR for mortality among patients with SCD–ESRD compared with 
those without SCD–ESRD was 2·95 (95% CI = 2·55–3·41).
The rate of death during the study period was higher among patients with SCD–ESRD when 
compared to those without SCD-associated ESRD (log rank test: P < 0·0001) (Fig 1). 
Twenty-six per cent of patients with incident SCD–ESRD died within the first year of 
haemodialysis. In the first year of dialysis, the fully adjusted HR for mortality among 
patients with SCD–ESRD compared to those without SCD–ESRD was 2·80 (95% CI 2·31–
3·38). In addition to SCD, patient characteristics independently associated with a higher rate 
of death were older age, males, ‘Black or African American’ race, and a higher BMI, as well 
as the presence of comorbid conditions (DM, CHF, CVA, PVD, and HxHT), decreased 
baseline glomerular filtration rate and haemoglobin levels, lower functional status 
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(amputation, inability to ambulate, and institutionalized), being unemployed at the time of 
the ESRD, and having no insurance.
The associations between risk of death and individual variables of pre-ESRD care during the 
follow-up period are shown in Table III. In the non-SCD–ESRD cohort the risk of premature 
death within the study period among those receiving any pre-dialysis nephrology care was 
significantly lower by 33% (HR = 0·67, 95% CI 0·45–0·99). The risk of death among 
patients with SCD–ESRD receiving pre-dialysis care for ≥6 months was not statistically 
different from that of the group that received pre-dialysis care for <6 months (HR = 0·75, 
95% CI 0·51–1·12). In contrast, among the ESRD haemodialysis population without SCD, 
early pre-dialysis care, defined as more than 6 months prior to the start of dialysis, was 
associated with a 22% (HR = 0·78, 95% CI 0·77-0·80) decrease in death when compared to 
receipt of pre-dialysis care for <6 months prior to dialysis.
The type of venous access used for the first dialysis was not associated with survival of 
patients with SCD–ESRD. Having an AVF at the start of haemodialysis was not associated 
with a significant reduction in mortality (HR = 0·79, 95% CI 0·34–1·83), nor was the use of 
a central venous catheter associated with an increase in risk of early death among those with 
SCD–ESRD (HR = 1·34, 95% CI 0·81–2·21). Data regarding the cause of death were 
available for two of the four study years (2005 and 2007). The most frequent causes of death 
for those with SCD were arrhythmia (33·3%) and infections (9·1%).
Discussion
In this population-based, cohort study using national renal surveillance data, 26% of incident 
ESRD patients with SCD as the primary cause of renal failure died within the first year of 
haemodialysis and mortality within the first year among this population was 2·8 times that of 
other patients with ESRD beginning haemodialysis during the same time period. Further, 
similar to other patients with ESRD, the risk of death among patients with SCD–ESRD was 
attenuated among those who received pre-dialysis nephrology care for a period of 6 or more 
months. Our finding that CKD among patients with SCD was associated with high mortality 
is consistent with previously reported evidence (Platt et al, 1994) and the increased risk of 
mortality associated with late referral to nephrology care is consistent with a number of 
recent reports for dialysis patients without SCD–ESRD (Bradbury et al, 2007; McClellan et 
al, 2009). In our study, patients with SCD–ESRD had higher mortality compared with other 
patients with ESRD despite their younger average age and the lower prevalence of specific 
comorbid conditions, such as DM and ASHD, that are associated with lower survival in the 
general dialysis population. These findings suggest that detection and appropriate, evidence-
based management of CKD among individuals with SCD might reduce the 26% 1 year death 
rate following the start of haemodialysis reported here.
A previous study of SCD–ESRD utilizing United States Renal Data System data noted 
increased mortality over longer periods of follow-up among individuals with ESRD due to 
SCD (National Kidney Foundation, 2001a) However, although SCD patients were less likely 
to be placed on the renal transplant waiting list and to receive a transplant, controlling for 
transplantation status eliminated the increased risk of death among SCD haemodialysis 
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patients. We were unable to account for transplantation status in the current analysis but, 
given the low rates of transplantation in individuals with SCD and the prolonged waiting 
times experienced by those on the transplant waiting list, we believe that transplantation 
status is unlikely to account for the patterns of early mortality that we observed.
While CKD might not be diagnosed until adulthood, evidence suggests that renal injury 
associated with SCD might start during infancy. A recent randomized, double-blinded, 
placebo-controlled trial (Ware et al, 2010) showed that, at baseline, infants with SCD 
demonstrated significant glomerular hyperfiltration. A study of an infant SCD cohort 
(Piepsz et al, 2006) found that the average baseline quantitative glomerular filtration rate 
measurement, determined by diethylenetriaminepentaacetic acid clearance, was 125 ml/min/
1·73 m2 (range from 40·2 to 300·9 ml/min/1·73 m2), a value considerably higher than the 
published normal value of 91·5 ml/min/1·73 m2 (10–90% range from 60 to 120 ml/min/1·73 
m2) for this age group. Another group reported that 4·2% of 725 individuals with SCD who 
were followed for 25 years developed renal failure and had a 40% higher risk of death 
during follow-up than their counterparts without renal failure (Powars et al, 1991). Further, 
the occurrence of renal insufficiency generally was evident by early adulthood (23 years). 
Thus, recommendations to improve outcomes for renal disease among individuals with SCD 
should start with the paediatric population and continue with practice guidelines addressing 
the transition of care from adolescence to adulthood. One possible reason that current 
clinical practice guidelines for CKD and ESRD lack specific recommendations for SCD care 
is the low incidence of the disease (Collins et al, 2009). However, despite the overall small 
proportion of patients with SCD, as the primary cause of ESRD, quality improvement 
activities targeted to this population are needed to improve outcomes.
Patients with SCD have complex medical problems that complicate both pre-ESRD care and 
renal replacement therapy. Unfortunately, we did not have data on the prevalence of 
pulmonary hypertension, and the incidence of pain or acute chest syndrome that have been 
associated with mortality among patients with SCD. We could not determine the extent to 
which the prevalence of these co-morbidities may contribute to the high mortality in this 
population. Nevertheless, early referral to a nephrologist may decrease the risk of death for 
SCD patients with CKD. Additional studies are needed to understand the relationships 
between early ESRD mortality and common complications experienced by patients with 
SCD. The applicability of existing guidelines for the early detection and management of 
kidney disease (National Kidney Foundation, 2001b, 2002) should be examined in relation 
to SCD. Further, given the strong relationship between ESRD and mortality in the first year 
following diagnosis of ESRD, future studies addressing other co-morbidities associated with 
risk of death in SCD, such as elevated triscuspid jet velocity, must either exclude or adjust 
for the presence of ESRD so results may be comparable from one study to the next.
Additional limitations to our study should be noted. First, others have demonstrated that 
there is misclassification of AVF status in data collected on the CMS–2728 form at the start 
of ESRD therapy (Piepsz et al, 2006). However, we believe this is unlikely as both the 
presence of an AVF and early pre-nephrology care data collected on the Form CMS–2728 
are strong predictors of improved survival. If individuals with SCD were consistently 
misclassified with respect to these measures (i.e. absent when actually present and the 
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converse) then we would expect an attenuation of the risks observed in our study. The 
misclassification is likely to be non-differential, resulting in an underestimate of the strength 
of the association; therefore, our finding of a strong association may be an underestimate. 
We were not able to demonstrate statistically significant relationships for all of our 
outcomes. It is probable that the lack of statistical significance was due to the small number 
of patients in our study with SCD–ESRD (n = 410). However, the magnitude and direction 
of our point estimates were consistent with a large body of literature on mortality in the 
ESRD population. Additionally, we were not able to confirm the diagnosis of SCD in the 
study sample. Thus, misclassification of patients with incident ESRD and SCD might have 
occurred. To limit misclassification, we restricted our analysis to patients with a diagnostic 
code of SCD as their primary cause of ESRD and excluded patients with SCD who had 
comorbid conditions, such as diabetes, leading to ESRD. Consequently, the prevalence of 
comorbid conditions among patients with ESRD who have SCD is probably understated. 
Most critically, the results cannot be generalized to the population of SCD with ESRD but 
only to those for whom SCD is the direct cause of ESRD.
Also, we used all-cause mortality in our analysis, as opposed to identifying the primary and 
secondary reasons for death. Such information might have strengthened the evidence that 
prior ESRD care among individuals with SCD–ESRD improved survival. However, all-
cause mortality has been used as an outcome after a diagnosis of ESRD in previous 
mortality studies (Pastan et al, 2002; McClellan et al, 2009), which enables comparisons 
across studies. Despite these limitations, our results are consistent with previous evidence 
that haemodialysis survival rates are increased with adequate pre-ESRD care.
In summary, ESRD patients with SCD as the primary cause of renal failure have a high rate 
of premature death, particularly in the first 12 months after the diagnosis, which might be 
attenuated with timely referral to a nephrologist. Further improvement in outcomes might be 
achieved by the development of evidence-based guidelines that are specific to the population 
with SCD. Future studies to identify risk factors for death should include the presence of 
ESRD as a potential confounder. Clinicians caring for this vulnerable population of patients 
should recognize the importance of early detection and appropriate management of CKD 
associated with SCD.
Acknowledgements
The analyses upon which this publication is based were performed under Contract Number HHSM-500-2010-005C, 
entitled ‘End Stage Renal Disease Networks Organization Number 5”, sponsored by the Centers for Medicare and 
Medicaid Services (CMS), Department of Health and Human Services.” This article is a direct result of the Health 
Care Quality Improvement Program initiated by CMS, which has encouraged identification of quality improvement 
projects derived from analysis of patterns of care, and therefore required no special funding on the part of this 
contractor. This research was supported in part by an appointment to the Research Participation Program at the 
Centers for Disease Control and Prevention, Division of Blood Disorders administered by the Oak Ridge Institute 
for Science and Education through an interagency agreement between the U.S. Department of Energy and the 
Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and 
do not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank Dr. 
Steven Embury and Mrs. Deborah Jones for reviewing and editing the manuscript.
McClellan et al. Page 8










Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW. 
Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and 
Practice Patterns Study (DOPPS). Clinical Journal of American Society of Nephrology. 2007; 2:89–
99.
Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, 
McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, 
Snyder J, Solid C, Wang C, Wein handl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, 
Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, 
Everson S, Eggers P, Agodoa L. United States Renal Data System 2008 Annual Data Report. 
American Journal of Kidney Diseases. 2009; 53:S1–S374.
Hassell KL. Population estimates of sickle cell disease in the U.S. American Journal of Preventive 
Medicine. 2010; 38:S512–S521. [PubMed: 20331952] 
McClellan WM, Wasse H, McClellan AC, Kipp A, Waller LA, Rocco MV. Treatment center and 
geographic variability in pre-ESRD care associate with increased mortality. Journal of the American 
Society of Nephrology. 2009; 20:1078–1085. [PubMed: 19321704] 
National Kidney Foundation. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: 
update 2000. American Journal of Kidney Diseases. 2001a; 37:S137–181. [PubMed: 11229969] 
National Kidney Foundation. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic 
Kidney Disease: update 2000. American Journal of Kidney Diseases. 2001b; 37:S182–238. 
[PubMed: 11229970] 
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: 
evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002; 39:S1–
266. [PubMed: 11904577] 
Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis 
patients. Kidney International. 2002; 62:620–626. [PubMed: 12110026] 
Piepsz A, Tondeur M, Ham H. Revisiting normal (51)Cr-ethylenediaminetetraacetic acid clearance 
values in children. European Journal of Nuclear Medicine and Molecular Training. 2006; 33:1477–
1482.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle 
cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine. 
1994; 330:1639–1644. [PubMed: 7993409] 
Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, Johnson C. Chronic renal failure 
in sickle cell disease: risk factors, clinical course, and mortality. Annals of Internal Medicine. 
1991; 115:614–620. [PubMed: 1892333] 
Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents 
with sickle cell disease. Blood. 2010; 115:3447–3452. [PubMed: 20194891] 
Ware RE, Rees RC, Sarnaik SA, Iyer RV, Alvarez OA, Casella JF, Shulkin BL, Shalaby-Rana E, 
Strife CF, Miller JH, Lane PA, Wang WC, Miller ST. Renal function in infants with sickle cell 
anemia: baseline data from the BABY HUG trial. Journal of Pediatrics. 2010; 156:66–70 e1. 
[PubMed: 19880138] 
McClellan et al. Page 9










Kaplan–Meier mortality survival curves (Up to 1,553 d (4·25 years) of survival) for incident 
end-stage renal disease (ESRD) haemodialysis patients with and without sickle cell disease 
as the primary cause of renal failure, (Log rank test: P < 0·0001) June 2005 to May 2009, N 
= 442 015. Incident ESRD patients without sickle cell disease (SCD) as the primary cause of 
renal failure, as recorded on Form CMS-2728. Incident ESRD patients with SCD as the 
primary cause of renal failure.
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Table I
Characteristics of end-stage renal disease patients with and without sickle cell disease as the primary cause of 
renal failure, starting haemodialysis during the period 1June 1, 2005, to 31 May, 2009, N = 442 017.
SCD–ESRD Non-SCD–ESRD OR (95% CI)*
All Black or AfricanAmerican White SCD–ESRD versus
non-SCD–ESRD
Characteristic n % n % n %
410 0·1 127 270 28·8 314 337 71·1
Demographic characteristics
Age (years)
 <65 396 96·6 82 138 64·5 145 829 46·4 –
 ≥65 14 3·4 45 114 35·5 168 469 53·6 0·06 (0·03–0·11)
Sex
 Male 219 53·4 65 710 51·6 182 100 57·9 0·85 (0·71–1·02)
 Female 191 46·6 61 560 48·4 132 237 42·1 –
Race as shown on Form CMS-2728
 Black or African American 400 97·6 127 270 100·0 – – 81·51 (35·61–186·55)
 White 10 2·4 – – 314 337 100·0
Comorbid conditions
 DM 18 4·4 58 546 46·0 148 264 47·2 0·08 (0·05–0·12)
 CHF 104 25·4 37 726 29·6 106 669 33·9 1·72 (1·39–2·13)
 ASHD 14 3·4 17 741 13·9 76 884 24·5 0·42 (0·21–0·85)
 CVA 33 8·1 12 710 10·0 29 353 9·3 1·39 (1·16–1·65)
 PVD 15 3·7 12 887 10·1 49 958 15·9 0·83 (0·48–1·43)
 HxHT 295 72·0 112 079 88·1 259 400 82·5 0·50 (0·41–0·60)
BMI (kg/m2)
 <25 302 74·2 43 545 34·4 116 073 37·2 –
 ≥25 105 25·8 82 943 65·6 196 294 62·8 0·21 (0·18–0·26)
Amputation 1 0·2 4004 3·2 10 091 3·2 0·19 (0·02–1·44)
Unable to ambulate 9 2·2 8280 6·5 22 163 7·1 0·60 (0·30–1·19)
Needs assistance 26 6·3 12 989 10·2 36 428 11·6 −1·19 (0·87–1·64)
Institutionalized 12 2·9 9096 7·2 25 092 8·0 0·63 (0·34–1·18)
Unemployment 172 42·0 33 180 26·1 47 878 15·2 1·40 (1·05–1·87)
No health insurance 23 5·6 14 082 11·1 18 947 6·0 0·23 (0·17–0·31)
SCD, sickle cell disease; ESRD, end-stage renal disease; OR, odds ratio; CI, confidence interval; DM, diabetics mellitus; CHF, congestive heart 
failure; ASHD, atherosclerotic heart disease; CVA, cerebrovascular disease; PVD, peripheral vascular disease; HxHT, history of hypertension; 
BMI, body mass index.
*OR adjusted for age category, sex, race (‘Black or African American’ versus ‘White’), DM, CHF, ASHD, CVA, PVD, HxHT, BMI, amputation, 
unable to ambulate, needs assistance, institutionalized, unemployed, no health insurance, and End Stage Renal Disease Network.
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Table II
Nephrology care among incident end-stage renal disease haemodialysis patients with and without sickle cell 
disease as the primary cause of renal failure, June 2005 to May 2009, N = 442 017.
SCD–ESRD Non-SCD–ESRD OR (95% CI)*




n = 127 270,%
Receiving care





Any pre-dialysis care 53·9 54·5 59·7 1·24 (1·04–1·48)
Pre-dialysis care > 6 months 43·9 44·0 48·5 1·25 (1·10–1·43)
Use of catheter at start of dialysis 76·1 77·2 75·2 0·95 (0·74–1·22)
AVF at start of dialysis  6·8 11·9 13·5 0·61 (0·40–0·92)
SCD, sickle cell disease; ESRD, end-stage renal disease; OR, odds ratio; CI, confidence interval; AVF, arteriovenous fistula.
*OR adjusted for age category, sex, race (‘Black or African American’ versus ‘White’), diabetics mellitus, congestive heart failure, atherosclerotic 
heart disease, cerebrovascular disease, peripheral vascular disease, history of hypertension, body mass index, amputation, inability to ambulate, 
institutionalized, unemployed, no health insurance, and End-Stage Renal Disease Network.
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Table III
One year mortality risk* among incident end-stage renal disease (ESRD) haemodialysis patients with sickle 
cell disease as the primary cause of renal failure, by pre-ESRD care and race, June 2005 to May 2009, n = 
410.
Precare measure HR (95% CI) for death† HR (95% CI) for death‡ HR (95% CI) for death§
Any pre-dialysis nephrologist care
 All 0·73 (0·50–1·06) 0·67 (0·45–0·99) 0·75 (0·51–1·10)
 Black or African American¶ 0·68 (0·46–1·00) 0·66 (0·44–0·97) 0·72 (0·49–1·06)
Pre-dialysis nephrologist care ≥6 months
 All 0·81 (0·55–1·19) 0·75 (0·51–1·12) 0·84 (0·57–1·23)
 Black or African American¶ 0·75 (0·51–1·17) 0·73 (0·49–1·08) 0·79 (0·54–1·17)
Use of catheter at start of dialysis
 All 1·48 (0·91–2·40) 1·34 (0·81–2·21) 1·34 (0·82–2·18)
 Black or African American¶ 1·48 (0·91–2·43) 1·32 (0·80–2·17) 1·34 (0·82–2·19)
AVF at start of dialysis
 All 0·75 (0·33–1·71) 0·79 (0·34–1·83) 0·73 (0·32–1·66)
 Black or African American¶ 0·78 (0·33–1·79) 0·79 (0·34–1·84) 0·72 (0·31–1·64)
HR, hazard ratio; CI, confidence interval; AVF, arteriovenous fistula.
*Up to 1,553 d (4·25 years) of survival.
†
HR adjusted for age, sex, race (‘Black or African American’ versus ‘White’), diabetes mellitus, history of hypertension, and body mass index 
(Model with 3 most prevalent comorbidities).
‡
HR adjusted for age category, sex, race (‘Black or African American’ versus ‘White’), diabetics mellitus, congestive heart failure, atherosclerotic 
heart disease, cerebrovascular disease, peripheral vascular disease, history of hypertension, body mass index, amputation; inability to ambulate, 
institutionalized, unemployed, and health insurance (Full model).
§
HR adjusted for congestive heart failure and inability to ambulate (Backward elimination model).
¶
In the models with Black or African American only the variable race (‘Black or African American’ versus ‘White’) was dropped.
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